Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


arGEN-X Initiates Phase Ib Study of ARGX-110 in Cancer

BREDA, the Netherlands, and GHENT, Belgium, January 7, 2013 /PRNewswire/ --

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery.

ARGX-110 is a first-in-class CD70-targeting monoclonal antibody that addresses both known mechanisms of action mediated by CD70: tumor cell proliferation and survival and tumor cell escape from immune surveillance.  In addition, POTELLIGENT® enhanced Antibody Dependent Cellular Cytotoxicity (ADCC) of ARGX-110 drives the selective destruction of CD70 positive tumor cells. The Phase Ib study will utilize a validated immunohistochemistry test to pre-screen patients for those whose tumors show up-regulation of CD70.

"CD70 expression is hijacked by cancer cells to stimulate their own growth and escape the body's immune surveillance. With ARGX-110 we are focusing on treating both the tumor and its immune environment with one molecule," said Alain Thibault, M.D., Chief Medical Officer at arGEN-X. "ARGX-110 is an excellent example of how our proprietary antibody discovery technologies can create exciting development candidates with unique and novel modes of action in cancer. We look forward to the results from this study and to further progress with this and other antibodies in our pipeline during the next 12 months."

In preclinical testing, ARGX-110 has shown broad therapeutic potential against CD70 positive lymphomas and lymphocytic leukemias, as well as solid tumors including those caused by oncogenic viruses, such as nasopharyngeal, cervical, and hepatocellular carcinomas. For Ahmad Awada, MD, PhD of the Jules Bordet institute and principal investigator of this trial, "CD70 may be a unifying driver mechanism for different subsets of cancer that are still poorly understood."

About the ARGX-110 Phase Ib Trial

The Phase Ib study being undertaken by arGEN-X is an adaptive dose escalation with safety expansion trial in around 54 patients, to be conducted by a consortium of leading academic institutions in Belgium.  In addition to traditional clinical and PK endpoints, biomarkers critical to understanding CD70 biology will be researched extensively in the course of the trial. Results on the recommended dose for future pivotal trials are expected by end Q4, 2013.

About arGEN-X

arGEN-X is a clinical stage biopharmaceutical company that is rapidly leveraging the power of its proprietary SIMPLE Antibody™ platform to generate fully human, highly differentiated antibodies with outstanding therapeutic potential. The platform excels in delivering large panels of ultra-potent, functionally diverse antibodies against complex disease targets, especially cell surface receptors and highly conserved proteins.

arGEN-X has validated its technology on multiple diverse target classes to date. Following a successful collaboration with Eli Lilly & Co., arGEN-X entered earlier this year into a strategic alliance with Shire, focused on the discovery and development of antibody therapeutics against complex targets implicated in rare diseases.

The superior choice that arGEN-X brings to antibody discovery enables it to prioritize leads with best-in-class therapeutic properties with an increased probability of development success. The consistent manufacturability of SIMPLE Antibody™ leads also makes for a seamless transition from discovery into development. Consequently, arGEN-X has developed a pipeline of therapeutic candidates in only three years of operations, the first of which, a novel anti-IL-6 monoclonal antibody, ARGX-109, was licensed to RuiYi in October 2012 for development and commercialization worldwide.

In November 2012, arGEN-X filed a first CTA for ARGX-110, its most advanced SIMPLE Antibody™ program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors, as well as in autoimmunity. A second CTA for ARGX-111, a novel anti-c-Met antibody to treat diverse solid tumors, is on track for filing in 2013.

arGEN-X is applying NHance™ and POTELLIGENT® technologies to complement the therapeutic properties of leads generated from its SIMPLE Antibody™ platform, both in partnership and for its proprietary pipeline. SIMPLE Antibody™ and NHance™ platforms are covered by broad patent claims, enjoy an independent, unencumbered patent position and are free of target gatekeeping restrictions.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV.

POTELLIGENT® is a deposited trademark of BioWa Inc.

For further information, please contact:

Citigate Dewe Rogerson
David Dible
Mark Swallow
Nina Enegren
T: +44-207-282-2949/2948/1050
E: david.dible@citigatedr.co.uk


arGEN-X
Tim Van Hauwermeiren, MSc, eMBA
Chief Executive Officer
T: +31-6-122-85-257
E: tim.vh@arGEN-X.com

Debbie Allen, Ph.D.
Senior Director, Business Development
T: +44-7974-979479
E: dallen@arGEN-X.com


About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
Cloud computing in the form of Infrastructure-as-a-Service (IaaS) has revolutionized the expectations of IT. Infrastructure that used to take weeks to months to provision is now available in minutes. Moreover, most of the traditional drawbacks associated with infrastructure have disap...
This is the third in a series of cloud predictions for 2015, starting with When the Walls Come Down, which predicted that workload migration (into the cloud) costs would drop by more than 50% in 2015; then continuing with The Cloud Startup Ecosystem Explosion, which predicted the impac...
Kirk Byers at SDN Central writes frequently on the topic of DevOps as it relates (and applies) to the network and recently introduced a list of seven DevOps principles that are applicable in an article entitled, "DevOps and the Chaos Monkey. " On this list is the notion of reducing var...
General Electric (GE) has been a household name for more than a century, thanks in large part to its role in making households easier to run. Starting with the light bulb invented by its founder, Thomas Edison, GE has been selling devices (“things”) to consumers throughout its 122-year...
With the growing number of CSS Preprocessors like LESS, Sass, Turbine, Stylus and Swith CSS to name a few, it’s hard to decide which to choose for your project, and which will provide the best CSS authoring. Rather than focus on evaluating every CSS Preprocessor (that would simply take...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE